US Patent 10,959,996: Scope, Claims, Expiration, Orange Book Status, and Deutetrabenazine Patent Landscape
US Patent 10,959,996 protects a dose-conversion and titration method for switching patients with Huntington’s disease chorea from tetrabenazine to deutetrabenazine. Its core coverage is a next-day transition using a defined conversion ratio of approximately 2:1 from tetrabenazine milligrams to deutetrabenazine milligrams, followed by weekly 6 mg/day titration based on chorea control and tolerability.
The patent is strategically important because it covers clinical use of the branded AUSTEDO treatment protocol rather than only the deutetrabenazine molecule, formulation, or manufacturing process. The principal infringement risk is therefore associated with generic labeling, prescribing instructions, promotional materials, or clinical use that directs patients to make the claimed switch.
What does US Patent 10,959,996 protect?
US Patent 10,959,996 protects a method of transitioning a human from tetrabenazine to deutetrabenazine for Huntington’s disease chorea. Claim 1 requires all of the following:
- The patient is receiving tetrabenazine.
- Tetrabenazine is discontinued.
- Deutetrabenazine is administered the next day.
- The starting deutetrabenazine dose corresponds to a specified tetrabenazine dose.
- The indication is chorea associated with Huntington’s disease.
The claimed conversion schedule is:
| Tetrabenazine daily dose |
Initial deutetrabenazine daily dose |
Ratio |
| 12.5 mg |
6 mg |
2.08:1 |
| 25 mg |
12 mg |
2.08:1 |
| 37.5 mg |
18 mg |
2.08:1 |
| 50 mg |
24 mg |
2.08:1 |
| 62.5 mg |
30 mg |
2.08:1 |
| 75 mg |
36 mg |
2.08:1 |
| 87.5 mg |
42 mg |
2.08:1 |
| 100 mg |
48 mg |
2.08:1 |
The conversion is not a simple tablet-strength substitution. The claim requires discontinuation of tetrabenazine and administration of deutetrabenazine on the following day. A same-day overlap, an unstructured physician-directed switch, or a transition outside the listed dose pairs may fall outside claim 1 unless another claim is implicated.
How broad is the claim scope?
The patent has a relatively narrow independent claim but a commercially meaningful group of dependent claims.
Core method limitations
Claim 1 is limited by:
- Human treatment.
- Huntington’s disease chorea.
- Prior tetrabenazine therapy.
- Immediate next-day initiation of deutetrabenazine.
- One of eight enumerated dose conversions.
The claim does not require a particular tablet formulation, tablet strength, brand name, CYP2D6 genotype, age group, treatment duration, or concomitant medication. It also does not require a specific clinical outcome beyond the transition itself.
This makes the claim potentially relevant to a generic product even if the generic manufacturer does not copy the brand’s formulation or manufacturing process. The principal issue would be whether the generic labeling induces the claimed transition.
Clinical-outcome claims
Claims 2 through 5 add clinical-performance limitations, including:
- At least a 0.5-point reduction in the Total Maximal Chorea score.
- At least a 15% reduction in chorea.
- At least a 10% reduction in chorea combined with specified motor, physical-function, swallowing, balance, safety, or QTcF outcomes.
- At least a 10% improvement in motor function combined with specified additional outcomes.
These claims are narrower than claim 1 because they require proof of clinical results. They may have greater evidentiary value in a clinical study or medical-record context but are more difficult to establish in an induced-infringement case unless the accused labeling expressly promotes the claimed outcomes.
Titration claims
Claims 8 through 17 cover a structured titration protocol:
- Assess control of abnormal involuntary movement after approximately one week.
- Increase deutetrabenazine by 6 mg/day when control is inadequate and the dose is tolerated.
- Repeat the assessment and escalation approximately weekly.
- Reduce the dose by 6 mg/day if a subsequent dose is not tolerated.
- Continue until chorea control is adequate and the dose is tolerable.
- Cap the total maximum daily dose at 48 mg or, in certain claims, 36 mg.
This group creates a second infringement pathway. A generic label that recommends a weekly 6 mg/day increase based on efficacy and tolerability could practice the titration claims even if the label does not reproduce every clinical-outcome limitation.
What are the key dependent claims?
| Claims |
Subject matter |
Commercial significance |
| 2-5 |
Chorea, motor, safety, QTcF and functional outcomes |
Narrow outcome-based protection |
| 6-7 |
Twice-daily dosing for initial doses of 12-48 mg |
Covers standard divided dosing |
| 8-11 |
Weekly assessment, 6 mg/day escalation, dose reduction and repeat titration |
Important label-based coverage |
| 12-17 |
6 mg starting dose, escalation and maximum-dose options |
Covers lower-dose and broader titration sequences |
| 18-20 |
36 mg maximum dose with strong CYP2D6 inhibitors |
Important for drug-interaction labeling |
| 21-35 |
Specific tetrabenazine-to-deutetrabenazine dose pairs and divided doses |
Dose-specific fallback claims |
| 36 |
At least maintenance of chorea control |
Broadens outcome protection beyond improvement |
| 37-40 |
Initial doses of 6-36 mg with strong CYP2D6 inhibitor use |
Interaction-specific protection |
Claims 18 through 20 are commercially relevant because the FDA labeling for deutetrabenazine limits the maximum recommended dose in patients receiving strong CYP2D6 inhibitors. The named inhibitors include fluoxetine, paroxetine, bupropion, quinidine, cinacalcet, and ritonavir.
Are there drafting defects in the claims?
Claims 25, 27, 29, 31, 33 and 35 depend on claim 22 rather than the apparently corresponding dose-pair claims. Claim 22 covers 25 mg tetrabenazine and 12 mg deutetrabenazine. As written, the later claims may therefore be limited to the 25 mg tetrabenazine pathway while adding different divided deutetrabenazine doses.
For example, claim 25 recites 9 mg plus 9 mg, but its dependency on claim 22 appears to associate that dosing with 25 mg tetrabenazine rather than the 37.5 mg pathway. Similar issues appear in claims 27, 29, 31, 33 and 35.
The practical effect depends on prosecution history, claim-construction principles, and whether a court treats the dependencies as intentional limitations or drafting errors subject to correction. The independent claim and the correctly dependent dose claims remain the principal enforcement assets.
When does US Patent 10,959,996 expire?
The patent is expected to expire in 2036 based on its underlying priority and filing dates, subject to patent-term adjustment, patent-term extension, terminal disclaimers and any applicable regulatory exclusivity.
| Event |
Approximate timing |
| Earliest priority period |
2016 |
| US application and prosecution |
2017-2021 |
| US patent grant |
March 30, 2021 |
| Expected ordinary patent expiration |
2036 |
| Small-molecule regulatory exclusivity |
Separate from patent term |
The exact enforceable expiration date should be taken from the USPTO patent record and Orange Book listing because patent-term adjustment can move the expiration date beyond the nominal 20-year term. The patent number is US 10,959,996 B2. [1]
What is the Orange Book status of US Patent 10,959,996?
US Patent 10,959,996 is associated with Teva’s deutetrabenazine product AUSTEDO and is listed among the patents protecting AUSTEDO drug products in FDA patent-listing materials. AUSTEDO was approved for chorea associated with Huntington’s disease and later for tardive dyskinesia. [2]
The Orange Book listing is commercially significant for two reasons:
- An ANDA applicant must address the listed patent through a Paragraph I, II, III or IV certification.
- A Paragraph IV certification can trigger patent litigation under the Hatch-Waxman framework.
Because US 10,959,996 claims a method of treatment, the principal generic challenge would likely focus on non-infringement, invalidity, or a section viii statement that the applicant is carving out the patented method. A section viii strategy is difficult if the FDA-approved product labeling necessarily instructs users to make the claimed tetrabenazine-to-deutetrabenazine transition.
Which companies are challenging AUSTEDO patent protection?
Generic manufacturers have pursued ANDA strategies for deutetrabenazine products, creating potential Paragraph IV disputes involving Teva’s AUSTEDO patent portfolio. Publicly reported AUSTEDO litigation has involved generic applicants including Hetero, Apotex, Sun Pharmaceutical and Dr. Reddy’s Laboratories in various proceedings concerning different AUSTEDO patents.
The risk is patent-specific. A challenge to a composition, polymorph, formulation or manufacturing patent does not automatically resolve the risk under US 10,959,996. A generic applicant may prevail against one patent while remaining blocked by another listed patent with a later expiration date.
The most important questions in a Paragraph IV case involving US 10,959,996 would be:
- Whether the proposed label directs a next-day transition from tetrabenazine.
- Whether the label contains the eight claimed dose conversions.
- Whether weekly 6 mg/day titration is recommended.
- Whether the label includes the 36 mg maximum dose for strong CYP2D6 inhibitor users.
- Whether the claims are anticipated or obvious over the Xenazine and AUSTEDO clinical-development record.
- Whether the claims are enabled and adequately supported for the full dose matrix.
- Whether the dependent-claim errors affect enforceability or construction.
What prior art creates validity risk?
The principal prior-art categories are:
Tetrabenazine labeling
XENAZINE labeling establishes tetrabenazine dosing for Huntington’s disease chorea, including titration and dose limitations. It supplies the starting-dose framework from which the patented conversion matrix is derived. [3]
Deutetrabenazine clinical and FDA materials
AUSTEDO labeling discloses deutetrabenazine dosing, divided administration, dose escalation, CYP2D6 restrictions and maximum doses. [2] The FDA-approved label may be relevant to written-description, enablement and obviousness analysis, even if it postdates the patent’s priority date.
Clinical transition studies
The patent’s strongest validity risk would arise from prepriority publications or clinical protocols describing a direct switch from tetrabenazine to deutetrabenazine using a roughly 2:1 conversion, followed by weekly 6 mg/day titration. A reference need not use the exact brand names if it discloses the same active ingredients, doses, timing and patient population.
The patent’s strongest defense is the combination of specific dose conversion, next-day administration, Huntington’s disease chorea, tolerability-based escalation and clinical maintenance or improvement.
How does this patent compare with other AUSTEDO patents?
| Patent category |
Typical subject matter |
Main risk to generic entry |
| Deutetrabenazine composition patents |
Deuterated VMAT2 inhibitor compounds |
Broad molecule-level protection |
| Salt, polymorph and solid-state patents |
Chemical forms and crystalline materials |
API and supply-chain barriers |
| Formulation patents |
Tablets, release profiles and excipients |
Product-specific infringement |
| Method-of-use patents |
Huntington’s chorea, tardive dyskinesia and dosing |
Label and prescribing risk |
| US 10,959,996 |
Switching from tetrabenazine to deutetrabenazine |
Induced-infringement and label carve-out risk |
| Manufacturing patents |
Preparation, purification and isotope incorporation |
API sourcing and process risk |
US 10,959,996 is narrower than a composition patent but can remain important after broader molecule claims become vulnerable. It protects a clinically practical conversion protocol that may be included in prescribing information, switching guides and medical education.
What generic entry risks exist?
A generic launch could follow several scenarios:
Full-label launch
A full-label ANDA reproducing the AUSTEDO indication and transition instructions would face the highest risk under US 10,959,996. Teva could argue that the label encourages physicians to perform the claimed next-day conversion and weekly titration.
Carved-out label
An applicant could attempt to remove the patented transition method under section viii. The success of that strategy would depend on whether the FDA-approved generic label can omit the switching instructions while retaining the underlying Huntington’s disease chorea indication.
Paragraph IV litigation and settlement
A Paragraph IV applicant could challenge validity or non-infringement and negotiate a settlement with a licensed or delayed entry date. Any settlement would need to be assessed against the patent’s expiration, other AUSTEDO patents and possible authorized-generic arrangements.
Launch after patent expiration
A post-expiration launch avoids the method patent but may still face other listed patents, regulatory exclusivity, supply constraints and manufacturing barriers.
Does biosimilar risk apply to deutetrabenazine?
No. Deutetrabenazine is a small-molecule drug, not a biologic. Competitors would generally use the ANDA pathway for an equivalent generic product rather than the biosimilar pathway under the Public Health Service Act.
The relevant regulatory issues are therefore:
- ANDA approval.
- Paragraph IV certifications.
- Section viii method-of-use carve-outs.
- Bioequivalence.
- Labeling.
- Patent litigation under the Hatch-Waxman Act.
What is the commercial exposure for Teva?
AUSTEDO is one of Teva’s principal growth products. Teva reported AUSTEDO net sales of approximately $1.5 billion in 2024, with continued growth in both Huntington’s disease chorea and tardive dyskinesia. [4]
The revenue exposure from US 10,959,996 is narrower than the exposure from molecule or formulation patents because the patent covers a specific Huntington’s disease switching method. Its economic value increases if:
- The FDA label expressly includes the patented transition.
- Physicians commonly switch patients from Xenazine to AUSTEDO.
- The conversion method reduces clinical friction during product conversion.
- Other patents expire before US 10,959,996.
- Teva uses the patent to delay or condition generic labeling.
Its value is lower if generic manufacturers can obtain approval with a clean label that omits the transition method or if the claims are invalidated in Paragraph IV litigation.
How strong is the patent estate for this method?
US 10,959,996 has moderate-to-strong practical coverage and narrower legal breadth.
Its strengths are:
- A clear eight-pair dose matrix.
- Direct relevance to a known clinical switching scenario.
- Coverage of next-day conversion.
- Dependent claims covering weekly titration.
- CYP2D6 inhibitor restrictions.
- Potential Orange Book leverage.
Its weaknesses are:
- The independent claim is limited to Huntington’s disease chorea.
- The dose matrix may be viewed as an optimization of known dosing.
- Many dependent claims require clinical outcomes that may be difficult to prove.
- Several claims contain apparent dependency errors.
- A generic applicant may seek a section viii carve-out.
- Clinical protocols or publications could create anticipation or obviousness arguments.
Key Takeaways
- US 10,959,996 covers switching patients from tetrabenazine to deutetrabenazine the next day for Huntington’s disease chorea.
- The core conversion is approximately 2:1, ranging from 12.5 mg tetrabenazine to 6 mg deutetrabenazine through 100 mg to 48 mg.
- Dependent claims cover twice-daily dosing, weekly 6 mg/day titration, dose reduction, maximum doses and strong CYP2D6 inhibitor use.
- The patent is associated with the AUSTEDO Orange Book patent estate.
- Expected expiration is in 2036, subject to the official patent-term calculation.
- Generic applicants face label-based induced-infringement risk if their ANDA labeling reproduces the switching protocol.
- No biosimilar pathway applies because deutetrabenazine is a small molecule.
- Claims 25, 27, 29, 31, 33 and 35 contain apparent dependency inconsistencies that may affect claim construction.
- The patent’s commercial value depends heavily on whether FDA-approved generic labeling can omit the patented switching instructions.
FAQs About US Patent 10,959,996
What drug does US Patent 10,959,996 protect?
It protects a method of transitioning a patient with Huntington’s disease chorea from tetrabenazine, marketed as XENAZINE, to deutetrabenazine, marketed as AUSTEDO.
Does the patent cover deutetrabenazine for tardive dyskinesia?
The claims provided are limited to chorea associated with Huntington’s disease. They do not expressly cover treatment of tardive dyskinesia.
Can a generic company avoid US 10,959,996 by using a different starting dose?
Potentially, if the proposed method does not practice any claimed dose pair or dependent titration limitation. Avoidance would depend on the actual label, physician instructions and patient-use evidence.
What is the maximum deutetrabenazine dose in the patent?
The claims identify a total maximum daily dose of 48 mg generally and 36 mg in certain patients receiving strong CYP2D6 inhibitors.
Is US 10,959,996 a formulation patent?
No. It is principally a method-of-treatment patent covering a clinical transition and titration regimen rather than tablet composition, excipients or manufacturing.
References
- United States Patent and Trademark Office. (2021). U.S. Patent No. 10,959,996, methods of transitioning from tetrabenazine to deutetrabenazine.
- U.S. Food and Drug Administration. (2024). AUSTEDO (deutetrabenazine) prescribing information. Teva Pharmaceuticals USA, Inc.
- U.S. Food and Drug Administration. (2024). XENAZINE (tetrabenazine) prescribing information.
- Teva Pharmaceutical Industries Ltd. (2025). 2024 annual report.
